ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Capricor Therapeutics Inc

Capricor Therapeutics Inc (CAPR)

6.76
0.37
(5.79%)
Closed March 19 04:00PM
6.80
0.04
(0.59%)
After Hours: 07:58PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
6.80
Bid
6.79
Ask
6.99
Volume
527,162
6.1001 Day's Range 6.91
2.68 52 Week Range 8.2212
Market Cap
Previous Close
6.39
Open
6.40
Last Trade
1
@
6.93
Last Trade Time
Financial Volume
$ 3,446,951
VWAP
6.5387
Average Volume (3m)
243,244
Shares Outstanding
30,792,869
Dividend Yield
-
PE Ratio
-7.21
Earnings Per Share (EPS)
-0.94
Revenue
2.55M
Net Profit
-29.02M

About Capricor Therapeutics Inc

Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell t... Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Capricor Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CAPR. The last closing price for Capricor Therapeutics was $6.39. Over the last year, Capricor Therapeutics shares have traded in a share price range of $ 2.68 to $ 8.2212.

Capricor Therapeutics currently has 30,792,869 shares outstanding. The market capitalization of Capricor Therapeutics is $209.08 million. Capricor Therapeutics has a price to earnings ratio (PE ratio) of -7.21.

CAPR Latest News

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy; Announced Successful Interim Futility Analysis; On Track to Report Top-Line Data in Q4 20...

Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy

SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- – Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevent...

Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and preventio...

Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization

-Cohort B of HOPE-3, Phase 3 Clinical Trial Expected to Complete Enrollment in Second Quarter 2024- SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology c...

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

-Project NextGen Collaboration will Support Capricor’s StealthX™ Exosome Platform and Provide Non-Dilutive Support for Advancement into the Clinic- SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Caprico...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.6911.29296235686.116.915.53807216.03566643CS
43.1485.79234972683.666.913.632962575.18394901CS
122.3552.8089887644.456.913.562432444.78061394CS
260.253.816793893136.556.912.682629933.9672516CS
522.3552.8089887644.458.22122.681815564.38681889CS
1561.5629.77099236645.248.22122.562619614.48334663CS
2606.2981254.581673310.50212.320.25267600105.83890001CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PIXYShiftPixy Inc
$ 6.80
(100.00%)
12.86M
STISolidion Technology Inc
$ 2.72
(56.32%)
90.62M
GOEVCanoo Inc
$ 2.9299
(51.03%)
108.38M
FRESFresh2 Group Ltd
$ 0.6903
(47.69%)
800.88k
AFIBAcutus Medical Inc
$ 0.2647
(35.81%)
6.92M
GMMGlobal Mofy Metaverse Ltd
$ 0.98
(-66.67%)
5.62M
SONDSonder Holdings Inc
$ 3.426
(-37.71%)
282.25k
WIMIWiMi Hologram Cloud Inc
$ 1.09
(-36.99%)
21.73M
WKSPWorksport Ltd
$ 0.47999
(-35.14%)
1.51M
MEDSTRxADE Health Inc
$ 19.60
(-31.94%)
165.37k
VERBVerb Technology Company Inc
$ 0.3589
(-18.84%)
248.26M
SQQQProShares UltraPro Short QQQ
$ 11.05
(-2.73%)
142.97M
GOEVCanoo Inc
$ 2.9299
(51.03%)
108.38M
TSLATesla Inc
$ 173.80
(6.25%)
108.21M
SOUNSoundHound AI Inc
$ 8.235
(-7.58%)
93.82M

CAPR Discussion

View Posts
starkd748 starkd748 8 hours ago
Haha looks like it
👍️0
enthalpy enthalpy 9 hours ago
I think it get to 8 next week or so. We will see!!! Gltu!!!
👍️0
starkd748 starkd748 14 hours ago
I'm waiting for 4s for a flip lol...Looks bearish
👍️0
enthalpy enthalpy 2 days ago
I doubled my position in the 4s. We will see. Secretly hoping for a green light on AA BLA in some form. So many other companies have a 500 million or billion dollar market cap and capr is right there but beaten down. At point it will get discovered.
👍️0
Volcano Volcano 1 week ago
I told you all
1000% runner here
👍️0
ed3/6me ed3/6me 2 weeks ago
would be a bigger player with my other holdings cooperation. Do not have volcanos view but feel it is a great vehicle for slow steady progress.
👍️0
enthalpy enthalpy 2 weeks ago
Hey Ed this is probably going to 8 this month at a minimum. Fingers crossed.
👍️0
ed3/6me ed3/6me 2 weeks ago
Sold some at 6 re bought at 4 so more shares and money
👍️0
GreedyAgorist GreedyAgorist 2 weeks ago
How did that work out for you, ed? Did you get some 5's assigned to you last month? I only picked up another 100 shares in February, after doing the same in January. It was December when I increased my position here by 60%. Now all those shares are up for grabs at 5. We will find out in 10 days if that is a bargain or not. At worst it will be a 25% gain in 3 months.

I only have one position in cash covered puts. Those will also expire on the 15th. It will be like scoring a 20% dividend out of something that does not pay a dividend.* Wish I had more put positions; I will the next time this "pos" dips. BTW, I trade this in an IRA, so no Wash Sale worries. I won't presently become a millionaire like Volcano. But maybe future me will.

Obvious statement: I am not ed3/6me's financial advisor or anyone else's. Just demonstrating how you can milk a ticker for almost monthly income without it being a blue chip dividend payer. I can't say it removes those anxious feelings you get when it dumps (or pumps), but it will remove some cash off the table.

*I could use more such scores to keep up with inflation; you know, just in case Biden scapegoating evil corporations doesn't do the trick.
👍️0
staynafloat staynafloat 3 weeks ago
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy

SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- – Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company has been granted an in-person Type-B meeting with the U.S. Food & Drug Administration (FDA) scheduled for late March. In the upcoming meeting with the FDA, the Company intends to discuss its proposed chemistry, manufacturing and controls (CMC) plans for commercial launch, if approved which may enable opportunities to expedite the pathway to a Biologics License Application (BLA) submission. The Company has previously been granted Regenerative Medicine Advanced Therapy (RMAT) and orphan drug designations for the use of CAP-1002 in Duchenne muscular dystrophy (DMD) and these designations enable sponsors to work closely with the FDA and receive its guidance on potential expedited pathways for approval.

“At this time, with our pivotal Phase 3, HOPE-3 trial fully enrolled in Cohort A and top-line data expected in the fourth quarter of this year, we believe that discussing our CMC plans for potential commercialization with the FDA will allow us the opportunity to bring CAP-1002 to patients in the most expeditious manner possible for patients in need,” said Linda Marbán, Ph.D., Capricor’s chief executive officer. “At Capricor, we remain focused on getting to approval as quickly as possible and we look forward to providing more details after this meeting.”

https://www.capricor.com/investors/news-events/press-releases/detail/271/capricor-therapeutics-announces-upcoming-type-b-meeting
👍️0
steadykickin steadykickin 3 weeks ago
https://www.capricor.com/investors/news-events/press-releases/detail/270/capricor-therapeutics-to-present-fourth-quarter-and-full February 29.
👍️0
Boom2013 Boom2013 4 weeks ago
https://www.capricor.com/investors/news-events/press-releases/detail/269/capricor-therapeutics-announces-manufacturing-scale-up-of
👍️0
steadykickin steadykickin 4 weeks ago
Capricor is pleased to be featured in a Scientific Session being held today at the International Duchenne Parent Project Italy Conference in Rome. To view the full agenda and additional details on the session please, click here: https://t.co/nOg382Rcj3 pic.twitter.com/pNg2sdUuHk— Capricor Therapeutics (@Capricor) February 17, 2024
👍️0
ed3/6me ed3/6me 1 month ago
Wrong
👍️0
stockplayer-11 stockplayer-11 1 month ago
Looks like nobody is interested in this shitty scam that'll never see FDA approval
👍️0
stockplayer-11 stockplayer-11 1 month ago
Damn your dumb ass can't even form a complete sentence.
👍️0
Volcano Volcano 1 month ago
Bcs you are ignorant and dumb
Why do you think huge Japanese bio firm made a deal?
They are much smarter than you dumbo
👍️0
stockplayer-11 stockplayer-11 1 month ago
You will not be be a millionaire. Will be no FDA approvals. You've been warned
👍️0
Volcano Volcano 1 month ago
I have huge shares here
I will be multi millionaire this year
I am so happy to hold long term
This is the year for FDA approval
👍️0
Volcano Volcano 1 month ago
It is coming
Be patient
We will be millionaires this year
$100 upon FDA approval
👍️0
PARker1703 PARker1703 2 months ago
When????? Been holding this pos for two years
👍️0
Volcano Volcano 2 months ago
Super huge news
👍️ 1
enthalpy enthalpy 2 months ago
K.
👍️0
PARker1703 PARker1703 2 months ago
Because the pumpers stopped posting
👍️0
enthalpy enthalpy 2 months ago
Fda meeting will happening shortly. Hopefully the get the greenlight this time.
👍️ 1
enthalpy enthalpy 2 months ago
On what grounds?
👍️0
ed3/6me ed3/6me 2 months ago
This unfunded part is their actual worth. If it gets teeth...they are going to the moon
👍️0
peterus peterus 2 months ago
going under 3s next few weeks
👍️0
dia76ca dia76ca 2 months ago
Steady progress on DMD is great. But the elephant in the room are the partnerships for the Exosome platforms.
Here is what the company has said...
"Exosome-Based Therapeutics and Vaccines (Preclinical): We are focused on developing a precision-engineered exosome platform technology that has the ability to deliver defined sets of effector molecules which exert their effects through defined mechanisms of action. We recently published preclinical data on our StealthXTM platform showing the rapid development of a recombinant protein-based.... At this time, we are developing vaccines and therapeutics for infectious diseases, monogenic diseases and other potential indications. Our platform builds on advances in fundamental RNA and protein science, targeting technology and manufacturing, providing us the opportunity to potentially build a broad pipeline of new therapeutic candidates. Our current strategy is FOCUSED on SECURING PARTNERS who will provide capital and additional resources..."
👍️0
dia76ca dia76ca 2 months ago
I forgot to add that they will also earn a Priority Review Voucher (PRV) which have sold recently for $110 million.
👍️0
enthalpy enthalpy 2 months ago
Lol well im okay with it. No reason really to go down. Ill hold out Q4 is almost here.
👍️0
dia76ca dia76ca 2 months ago
The recent $10 million milestone is only the start. There is another $90 million coming upon approval. And another $600 million in future milestones. And the ROW rights outside US and Japan should be significant. And very few shares out. Future exosome partnerships could be huge...with buy-out potential anytime IMO.
👍️0
peterus peterus 2 months ago
sell the news lol
👍️0
ed3/6me ed3/6me 2 months ago
Good for us . Right Enthalpy!
👍️0
PARker1703 PARker1703 2 months ago
You get 10mil and the stock goes down….pos
👍️0
enthalpy enthalpy 2 months ago
It is volcano time. Fingers crossed next 2 weeks we get some updates.
👍️0
ed3/6me ed3/6me 2 months ago
Trying your way
Y
👍️0
Volcano Volcano 2 months ago
I am looking forward to $100 price target this year
Pps will keep going up with the anticipation of BLA next month
I feel FDA will approve BLA this time
👍️0
ed3/6me ed3/6me 2 months ago
see this is finally getting recognised as what its potential is in the market. regenerative science sees potential here for rebuilding cells on a molecular level and this can springboard that research into all aspects of medicine as its basic potential to booster all known treatment plans going forward. read the research and make your own determination. I will be here till its true value is unlocked.
👍️0
GreedyAgorist GreedyAgorist 2 months ago
Buy low sell high has worked so far with this one. Or in my case, sell low and sell high. When it drops, I sell puts, and when it pops, I sell calls. (That's my way of getting "dividends" out of something that does not pay dividends.) Another spike and my Jun 7.5 order should catch.

I don't have quite as many shares as you do. Mine only account for 10% of one of my IRAs. But I am enjoying this recent rally all the same.
: - )
👍️0
XWAVXALMIMAN XWAVXALMIMAN 2 months ago
Good day. I’m holding my 50,000 shares. I sold some over 6 and bought back in low 3’s. I hope we get to 100 but I’ll be happy with double digits. Nothing goes straight up. 1/4 or 1/5 of position on a run to 7-8 and buying back at 5 lowers your average cost. If I’m wrong and we keep going up, that’s fine too. Everything takes longer than you think. Luckily we have great products and ideas and money to survive.
👍️0
ed3/6me ed3/6me 3 months ago
a little pullback today. understandable
👍️0
D-bol D-bol 3 months ago
Can’t wait
👍️0
peterus peterus 3 months ago
i know still here
👍️0
enthalpy enthalpy 3 months ago
BLA is coming 2024!!!!
👍️0
ed3/6me ed3/6me 3 months ago
Should be part of your portfolio anyway!
👍️0
Volcano Volcano 3 months ago
Many ppl will regret not buying now
This is $100 upon FDA approval
So much undervalued
I am holding until $100 per share next year
👍️0
ed3/6me ed3/6me 3 months ago
I can only reply to this one. and it really is a stock (specially at this price) i and you should have in our portfolio. Their aim is one we all can apreciate. and as long as this is part of their research and aim I for one will be here. Not always as a cheerleader but as a participant.
👍️0
peterus peterus 3 months ago
lol
👍️0
peterus peterus 3 months ago
geez man
the man pumps on every board
get real
👍️0

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com